Prosetta's Clinical & Scientific Advisory Board


Dr. Jairam Lingappa


Dr. Lingappa has been a faculty member at the University of Washington since 2004 and is currently an Professor in the Departments of Global Health and Medicine and Adjunct Professor in the Department of Pediatrics.  He received his B.A. in Physics from Swarthmore College, Ph.D. in Biophysics at Harvard University and M.D. at the University of California. He completed residency training in Pediatrics and a fellowship in Pediatric Infectious Diseases at the University of Washington.  From 1998 to 2003, he served as an officer with the US Public Health Epidemic Intelligence Service and subsequently as a medical epidemiologist at the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia. 

Since joining the UW faculty, he has collaborated with Drs. Connie Celum and Jared Baeten within the Department of Global Health International Clinical Research Center to conduct HIV-1 prevention clinical trials and observational studies in African heterosexual HIV-1 discordant couples.  More recently, his activities have focused on using samples and data from those HIV-1 serodiscordant couples cohorts to conduct translational research studies to understand the pathogenesis of HIV-1 sexual transmission and particularly to identify host biological correlates for risk of HIV-1 infection.



Dr. Robert Prust

Dr. Prust received his B.S degree from the University of Michigan in 1976, M.S. degree in Biochemistry from Wayne State University in 1981, and M.D. degree from Wayne State University in 1982, followed by a residency and fellowship in Radiation Oncology at the University of Michigan.  Since 1998, Robert has pursued a career in the clinical practice of Radiation Oncology at Munson Medical Center in Traverse City, Michigan.  He is an active member in the American Society for Radiation Oncology and the American Board of Radiology.





Dale Bredesen, MD


Dr. Dale Bredesen is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease.  His research focuses on the mechanisms of cell death in the nervous system and has led to a new approach to Alzheimer’s disease therapeutics.

Dr. Bredesen earned his undergraduate degree at Caltech, his MD at Duke University, and completed his neurology residency at UCSF.  

He was an NIH Fellow in the laboratory of Nobel Laureate Stanley Prusiner.  In 1989 he joined the faculty at UCLA, where he was awarded the Elizabeth R. and Thomas E. Plott Chair.  In 1994, he was recruited to the Burnham Institute to direct the Program on Aging, and then in 1998 became the Founding President and CEO of the Buck Institute for Research on Aging, the nation’s only independent institute devoted to research on aging and age- associated disease.  

He has held faculty positions at UCSF, UCLA and the University of California, San Diego.

He recently completed a term as a member of the National Advisory Council on Aging.  The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 200 research papers.  He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease.  His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the MEND protocol.